The anti-malarial drug HCQ was left out of the WHO Solidarity trial and the USFDA emergency use list this week. Doctors in India say they don’t see any major side-effects from its use.
‘The Lancet’ retracted a key study that linked anti-malarial drug HCQ to increased risk of death and irregularity in heart rhythms in coronavirus patients.
Mandeep R. Mehra, who graduated from a medical college in Maharashtra, is now a professor at Harvard, while Sapan S. Desai founded the data analytics firm Surgisphere.
In episode 489 of #CutTheClutter, Shekhar Gupta discusses the controversial studies that were retracted after scientists around the world raised questions on its data accuracy.
Three of the four authors of the study apologised to The Lancet's editors and readership for any embarrassment or inconvenience their published findings may have caused.
Questions have been raised on the Lancet HCQ study over dataset and methodology. Another journal has issued similar concern over a study that used same data.
More than a hundred scientists have raised questions about the dataset used in the study published by The Lancet, which led to WHO halting all trials of HCQ.
Doctors have identified hypertension or high blood pressure as ‘a key dangerous factor’ that leads to distress and death in patients with the coronavirus.
What do Indians want in a democracy? Quick and decisive action that may not have political consensus or frustratingly slow decision-making that endures long after the decision is made?
Air India’s new policy, effective from 2 May, introduces new weight limits for tickets in each of the different 'fare families' — Comfort, Comfort Plus, and Flex.
New Delhi has, in past, too, objected to Chinese construction activities in Shaksgam Valley. Work in this strategic region gathered pace after the 2017 Doklam stand-off.
A theme has not yet emerged for BJP & people see lack of a contest, which makes it unexciting. For all these reasons, 2024 is turning out to be an unexpectedly theme-less election.
COMMENTS